ipratropium

(redirected from Atrovent HFA)
Also found in: Medical.
Related to Atrovent HFA: Symbicort, Ventolin HFA

ip·ra·tro·pi·um

 (ĭp′rə-trō′pē-əm)
n.
An inhalant bronchodilator drug, C20H30NO3, used in the form of its bromide to treat obstructive pulmonary disease.

[Shortening of isopropylnoratropinium : iso- + propyl + nor- + atropin(e) + -ium.]

ipratropium

(ˌaɪprəˈtrəʊpɪəm)
n
(Recreational Drugs) drugs an anticholinergic bronchodilator that is used esp in the treatment of certain forms of asthma
References in periodicals archive ?
Atrovent HFA was recently approved but won't be available until later this year.
Atrovent HFA is the latest inhalation aerosol approved by the Food and Drug Administration after reformulation without CFCs; others include fluticasone HFA (Flovent HFA Inhalation Aerosol, GlaxoSmithKline) and two formulations of albuterol sulfate HFA (Proventil HFA, 3M Pharmaceuticals; Ventolin HFA, GlaxoSmithKline).
Atrovent HFA Inhalation Aerosol is for patients 12 years and older.
A randomized, double-blind study of four doses of PT001 (GP MDI) compared to placebo and Atrovent HFA inhalation aerosol, a short-acting muscarinic antagonist;
Shipments of ATROVENT HFA will begin arriving at pharmacies across the United States over the next several weeks, so physicians are now able to prescribe the new product to their COPD patients.
ATROVENT HFA is a formulation that was developed to provide patients a therapeutic benefit comparable to the existing chlorofluorocarbon (CFC) version of Atrovent(R) (ipratropium bromide) Inhalation Aerosol, a leading treatment for COPD.
ATROVENT HFA is a new drug formulation that was developed to provide COPD patients a therapeutic benefit comparable to ATROVENT (ipratropium bromide) (CFC) Inhalation Aerosol, a leading treatment for COPD.